Strides Shasun is currently trading at Rs. 1205.00, up by 124.70 points or 11.54% from its previous closing of Rs. 1080.30 on the BSE.
The scrip opened at Rs. 1100.00 and has touched a high and low of Rs. 1259.00 and Rs. 1093.00 respectively. So far 290856 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1259.00 on 03-Feb-2016 and a 52 week low of Rs. 848.00 on 29-Feb-2016.
Last one week high and low of the scrip stood at Rs. 1259.00 and Rs. 1052.95 respectively. The current market cap of the company is Rs. 10737.65 crore.
The promoters holding in the company stood at 31.14%, while Institutions and Non-Institutions held 49.05% and 19.81% respectively.
Strides Shasun’s subsidiary, Strides Pharma Global, Singapore has received tentative approval from the United States Food & Drug Administration (USFDA) for its Para IV filing of Fingolimod Capsules, 0.5 mg. The product can be launched on generic market formation expected in February 2019, with a potential 180 day exclusivity.
Fingolimod Capsules is used for treatment of adult patients with relapsing forms of multiple sclerosis. The product is currently sold by Novartis under the brand name GILENYA. According to IMS data, the US market for Fingolimod Capsules is around $2 billion. Fingolimod Capsules registered a healthy CAGR of 10 % over last 5 years as per IMS December 2016 MAT data.
Strides Shasun (formerly known as Strides Arcolab) is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.